Yakira Capital Management Urges Atrium Therapeutics Board to Initiate Strategic Review

Article summary

Shareholder Yakira Capital Management has publicly called on the Board of Atrium Therapeutics to conduct a strategic review, reduce cash burn, and provide transparency regarding a recent $50 million private placement.